Covid-19 roundup: Pfizer/BioNTech spell out PhIII priority; Legal experts urge FDA to refrain from vaccine EUAs
Milder side effects among the elderly were critical in Pfizer and BioNTech’s choice of vaccine candidate to send into Phase III testing, the companies revealed in a preprint.
The German biotech distinguished its Covid-19 program right from the beginning by evaluating four different mRNA constructs. BNT162b1 and BNT162b2, two nucleoside-modified RNAs formulated in lipid nanoparticles, showed the most promising results in animal studies and received fast track status in the US.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.